Panbela Therapeutics, Inc.: Nasdaq/NYSE listing notice — Panbela faces Nasdaq delisting over public float shortfall; ASPIRE trial enrollment >50%

Panbela Therapeutics, Inc.

Nasdaq staff notified Panbela that after 1-for-20 reverse split on Jan 18, publicly held shares fell below 500,000 minimum.
Delisting hearing scheduled for bid price and equity compliance; this additional non-compliance basis will be considered by panel.
Common stock remains listed on Nasdaq Capital Market pending hearing outcome; no assurance of continued listing.
ASPIRE global phase 3 trial for ivospemin in metastatic pancreatic cancer exceeded 50% enrollment; interim data expected mid-2024.
Full enrollment projected by Q1 2025; trial has about 90 sites across US, Europe, Australia, and South Korea.

item 3.01 item 7.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(a)(4)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5550(a)(4)

Exact text from the filing

January 22, 2024, Panbela Therapeutics, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as of effective date of the previously reported 1-for-20 reverse stock split on January 18, 2024, the Company was no longer in compliance with Nasdaq Listing Rule 5550(a)(4) (the “Minimum Float Requirement”), which requires a minimum of 500,000 publicly held shares. The Staff informed the Company that this matter serves as an additional basis for delisting the Company’s common stock and that the Nasda

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-24-002083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.